KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial.

Yanhua Zhao, Yuqing Ren, Wenqin Xie, Yulan Wang, Yishan Lei, Yingxia Zhu, Xiaoqing Zhang, Xiaozhi Wu, Xiaoming Guo, Yingying Jiang, Saiying Wang, Qian Lei, Jiyue You, Yonghao Yu, Yinhui Zhou, Wenjuan Zhou, Guohai Xu, Chang Li, Zhengfeng Gu, Foquan Luo, Hongfa Wang, Junping Chen, Ruichun Wang, Youmao Qi, Qing Jie, Diansan Su, Xiyao Gu, Weifeng Yu

Br J Anaesth 135(2) 331-339

PMID40461346
PMCID-
DOI10.1016/j.bja.2025.04.031
发表日期2025-06-03
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Adamgammadex, a newly developed modified γ-cyclodextrin derivative, has demonstrated efficacy in reversing deep rocuronium-induced neuromuscular block in early clinical trials. METHODS: This multicentre, randomised, double-blind, positive-controlled, noninferiority phase III clinical trial aimed to investigate the efficacy and safety of adamagammadex compared with sugammadex in reversing deep rocuronium-induced neuromuscular block. In total, 321 patients were randomly assigned to either the adamgammadex 8 mg kg-1 group or the sugammadex 4 mg kg-1 group. The primary outcome was the success rate of antagonism, defined as recovery of the train-of-four ratio (TOFR) to 0.9 within 10 min. Standard safety data were collected throughout the trial period. RESULTS: For the primary efficacy outcome, the success rate for recovery of TOFR to 0.9 was 98.7% in the adamgammadex group and 100% in the sugammadex group, with an observed difference of -1.3% (95% confidence interval [CI] -4.6%, 1.2%). The lower limit of -4.6% was higher than the noninferiority margin of -10%. For the key secondary efficacy outcomes, the median (interquartile range) time from administration of adamgammadex or sugammadex to recovery of TOFR to 0.9 was 2.5 (2.0, 3.2) min and 2.2 (1.7, 2.7) min, respectively. The difference was 0.5 min (95% CI 0.3, 0.7), and the upper limit of 0.7 min was lower than the noninferiority margin of 5 min. We observed no inferiority in secondary efficacy outcomes. There was no significant difference in the safety profile between adamgammadex and sugammadex. CONCLUSIONS: Adamgammadex was noninferior to sugammadex in reversing deep neuromuscular block from rocuronium. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2200056471, registered February 6, 2022; https://www.chictr.org.cn/showproj.html?proj=141077).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。